© 2018; Vinca Inst Nuclear Sci. All rights reserved. Strong beta emitters, like 90 Y, 177 Lu labelled peptide, are used for treatment of neuroendocrine tumours where there is a good expression of somatostatin receptors. In this work, MCNP5/X computer software and ORNL human phantoms were used lo calculate absorbed dose due to 90 Y labelled DOTATOC in the peptide receptor radionuclide therapy. Tumour was considered as a sources of beta radiation and represented as a sphere with diameter of 1-4 cm and 5 cm in liver, pancreas, and lungs. Results are expressed as absorbed dose per unit of cumulated activity, S -value in units mGy(MBq.s) -1 . The far largest dose is in tumour itself, then in organ which contains the tumour. Doses in other organ...
[[sup 90]Y]DOTA-DPhe[sup 1]-Tyr[sup 3]-octreotide ([[sup 90]Y]SMT487) has been suggested as a promis...
PURPOSE: An important assumption in dosimetry prior to radionuclide therapy is the equivalence of pr...
The aim of the study was to provide dosimetric data on intrahepatic 111In-diethylenetriaminepentaace...
Strong beta emitters, like 90Y, 177Lu labelled peptide, are used for treatment of neuroendocrine tum...
The challenge for internal therapy is to deliver the highest possible dose to the tumor while sparin...
Purpose: Peptide receptor radionuclide therapy with 177Lu-DOTATATE has become a standard treatment m...
Clinical trials on 177Lu 90Y therapy used empirical activity ratios. Radionuclides (RN) with larger ...
Biokinetic model is a mathematical model which describes the behavior of the 90Y in human body durin...
In this study, the absorbed dose of human organs after injection of 177Lu-DOTATOC was studied based ...
Peptide receptor radionuclide therapy for the internal radiation of neuroendocrine tumours expressin...
The somatostatin analogue (90)Y-DOTATOC (yttrium-90 DOTA- D-Phe(1)-Tyr(3)-octreotide) is used for tr...
Patient-specific image-based dosimetry is considered to be a useful tool to limit toxicity associate...
Neuroendocrine tumors express somatostatin receptors at the cell surface. In molecular imaging, this...
Introduction: In Peptide Receptor Radionuclide Therapy (PRRT), the administration of radionuclide su...
Peptide receptor radionuclide therapy (PRRT) using somatostatin analogues labeled with beta-particle...
[[sup 90]Y]DOTA-DPhe[sup 1]-Tyr[sup 3]-octreotide ([[sup 90]Y]SMT487) has been suggested as a promis...
PURPOSE: An important assumption in dosimetry prior to radionuclide therapy is the equivalence of pr...
The aim of the study was to provide dosimetric data on intrahepatic 111In-diethylenetriaminepentaace...
Strong beta emitters, like 90Y, 177Lu labelled peptide, are used for treatment of neuroendocrine tum...
The challenge for internal therapy is to deliver the highest possible dose to the tumor while sparin...
Purpose: Peptide receptor radionuclide therapy with 177Lu-DOTATATE has become a standard treatment m...
Clinical trials on 177Lu 90Y therapy used empirical activity ratios. Radionuclides (RN) with larger ...
Biokinetic model is a mathematical model which describes the behavior of the 90Y in human body durin...
In this study, the absorbed dose of human organs after injection of 177Lu-DOTATOC was studied based ...
Peptide receptor radionuclide therapy for the internal radiation of neuroendocrine tumours expressin...
The somatostatin analogue (90)Y-DOTATOC (yttrium-90 DOTA- D-Phe(1)-Tyr(3)-octreotide) is used for tr...
Patient-specific image-based dosimetry is considered to be a useful tool to limit toxicity associate...
Neuroendocrine tumors express somatostatin receptors at the cell surface. In molecular imaging, this...
Introduction: In Peptide Receptor Radionuclide Therapy (PRRT), the administration of radionuclide su...
Peptide receptor radionuclide therapy (PRRT) using somatostatin analogues labeled with beta-particle...
[[sup 90]Y]DOTA-DPhe[sup 1]-Tyr[sup 3]-octreotide ([[sup 90]Y]SMT487) has been suggested as a promis...
PURPOSE: An important assumption in dosimetry prior to radionuclide therapy is the equivalence of pr...
The aim of the study was to provide dosimetric data on intrahepatic 111In-diethylenetriaminepentaace...